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MaTraditional approaches to the characterization of secondary or functional mitral regurgitation (MR) have largely ignored
the critical importance of the left ventricle (LV). We propose that patients with secondary MR represent a heterogenous
group, which can be usefully subdivided based on understanding that the effective regurgitant oriﬁce area (EROA) is
dependent on left ventricular end-diastolic volume (LVEDV). According to the Gorlin hydraulic oriﬁce equation, patients
with heart failure, an LV ejection fraction of 30%, an LVEDV of 220 to 250 ml, and a regurgitant fraction of 50% would
be expected to have an EROA of z0.3 cm2 independent of speciﬁc tethering abnormalities of the mitral valve leaﬂets.
The MR in these patients is proportionate to the degree of LV dilatation and can respond to drugs and devices that reduce
LVEDV. In contrast, patients with EROA of 0.3 to 0.4 cm2 but with LVEDV of only 160 to 200 ml exhibit degrees of MR
that are disproportionately higher than predicted by LVEDV. These patients appear to preferentially beneﬁt from in-
terventions directed at the mitral valve. Our proposed conceptual framework explains the apparently discordant results
from 2 recent randomized controlled trials of mitral valve repair. The MITRA-FR (Percutaneous Repair with the MitraClip
Device for Severe Functional/Secondary Mitral Regurgitation) trial enrolled patients who had MR that was proportionate
to the degree of LV dilatation, and during long-term follow-up, the LVEDV and clinical outcomes of these patients did not
differ from medically-treated control subjects. In comparison, the patients enrolled in the COAPT (Cardiovascular Out-
comes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation)
trial had an EROA z30% higher but LV volumes that were z30% smaller, indicative of disproportionate MR. In these
patients, transcatheter mitral valve repair reduced the risk of death and hospitalization for heart failure, and these beneﬁts
were paralleled by a meaningful decrease in LVEDV. Thus, characterization of MR as proportionate or disproportionate to
LVEDV appears to be critical to the selection of an optimal treatment for patients with chronic heart failure and systolic
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ABBR EV I A T I ON S
AND ACRONYMS
EROA = effective regurgitant
oriﬁce area
LA = left atrium
LV = left ventricle/ventricular
LVEDV = left ventricular end-
diastolic volume
LVEF = left ventricular ejection
fraction
MR = mitral regurgitation
PISA = proximal isovelocity
surface area
Grayburn et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 8
Proportionate and Disproportionate FMR - 2 0 1 8 :- –-
2normal leaﬂets caused by global or regional
derangements of the left ventricle (LV).
The most common cause of primary MR in
developed countries is myxomatous degen-
eration, which can present as prolapse or a
ﬂail leaﬂet. Severe degenerative MR is treated
by surgical repair of the mitral valve, which is
associated with highly favorable and durable
outcomes and a very low mortality rate (2). In
contrast, post-inﬂammatory causes of pri-
mary MR (e.g., rheumatic heart disease,
endocarditis, and radiation) typically require
mitral valve replacement. The treatment op-
tions for primary MR are not controversial.However, the management of secondary or func-
tional MR presents signiﬁcant challenges. Because
this type of MR is largely related to a disease process
in the LV (and not the mitral valve), therapy is pri-
marily directed toward the underlying LV disorder.
The optimal use of neurohormonal antagonists and
resynchronization devices can lead to reversal of the
adverse remodeling process; the resulting reduction
in LV volumes can ameliorate the severity of MR in a
large proportion of patients (3–5). In contrast, surgical
interventions directed at the mitral valve have
yielded disappointing results. In 2 randomized
controlled clinical trials of patients with moderate or
severe MR due to ischemic disease but with relatively
preserved LV function (ejection fraction z40%),
mitral valve repair using a downsized annuloplasty
ring or chordal-sparing mitral valve replacement
failed to achieve pre-speciﬁed beneﬁts on cardiac
geometry, had no long-term favorable effects on
clinical outcomes, and had a high rate of recurrent MR
(6,7). Consequently, the management of secondary or
functional MR has focused on the restoration of LV
structure and function with drugs and devices, rather
than the use of direct mechanical interventions to
reduce MR.
Despite the apparent consistency of these out-
comes, it seems likely that patients with secondary
MR represent a heterogenous group, which may
include: 1) those whose MR is entirely explained by
the global distortions in mitral valve function pro-
duced by marked enlargement of the LV cavity; and 2)
those in whom the disease process within the LV acts
to disproportionately injure the segments of ventric-
ular muscle that support normal mitral valve coap-
tation. When compared with the former group, the
MR in the latter group might not be adequately
ameliorated by treatments that aim to achieve a
reduction in LV size, and might respond to in-
terventions that directly reduce the degree of MRthrough mechanical means. Accordingly, the ques-
tions that have befuddled cardiologists are: 1) if sec-
ondary MR is a disease of the LV, can interventions
that target the mitral valve still help in certain pa-
tients; and 2) how can we identify the distinct subset
of patients that beneﬁts from mitral valve repair?
During the past decade, technological advances
have greatly enhanced our ability to characterize the
dynamics of MR, allowing quantitative estimation
of regurgitant volume as well as the effective regur-
gitant oriﬁce area (EROA) (8). We can also evaluate
the various determinants of MR, including the posi-
tioning of the valve leaﬂets and the geometric
and functional distortions created by LV dilatation
(9). Most importantly, the results of randomized
controlled clinical trials of mitral valve repair in pa-
tients with systolic dysfunction have provided crit-
ical information about the range of responses to
therapeutic interventions that aim to reduce the
EROA in different groups of individuals (10–13). The
totality of the evidence suggests that we are now able
to identify patients with functional MR that beneﬁt
from a transcatheter procedure that is directed at the
mitral valve.
We propose a new conceptual framework that
distinguishes amongst the heterogenous group of
patients who have functional MR due to LV disease.
Our novel paradigm provides a strong pathophysio-
logical basis for selecting patients for specialized in-
terventions, explains the apparently discordant
ﬁndings from randomized trials, and can be further
tested by analyzing existing databases and perform-
ing additional studies.
EVOLUTION OF OUR CHARACTERIZATION
OF MR
To explain the rationale for proposing a new frame-
work, it is useful to ﬁrst consider the merits and de-
ﬁciencies of existing conceptual approaches that are
currently utilized to characterize and quantify MR.
Traditionally, physicians have distinguished primary
from secondary MR based on: 1) anatomy (i.e., iden-
tiﬁcation of the speciﬁc structural defect that caused
MR); or 2) time (i.e., elucidation of the sequence of
events in an effort to localize the lesion that initiated
the disease process). In addition, physicians have
attempted to quantify the magnitude of MR either by:
1) measuring the severity of MR by echocardiography;
or 2) assessing the presumed effect of regurgitant
ﬂow on the clinical course and prognosis of the pa-
tient. Each of these approaches to the characteriza-
tion of MR has important limitations.
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3PITFALLS OF CHARACTERIZING MR BASED ON
ANATOMY OR TIME. It is appealing to think that a
careful delineation of anatomy should be able to
guide clinical decision-making; for example, if the
valve is structurally diseased, then treatment should
be directed towards its repair or replacement. How-
ever, a pure focus on anatomy can be misleading. In
patients with an acute ischemic rupture of the
papillary muscle, the mitral valve leaﬂets are not
diseased, but instead, a highly localized injury of the
ventricular muscle precipitates the clinical presenta-
tion, and surgical replacement or repair of the mitral
valve can produce dramatic clinical beneﬁts in this
disorder (14). If replacement of the mitral valve sta-
bilizes the clinical course of patients whose principal
defect resides in the LV, then any classiﬁcation that
rigidly links treatment to the site of the anatomical
lesion may not provide a useful framework for
selecting the optimal management for speciﬁc
patients.
Theoretically, the conceptual difﬁculties raised by
acute ischemic rupture of the papillary muscle could
be resolved if patients with MR were classiﬁed prin-
cipally based on the presumed sequence of events
over time, rather than anatomy. Speciﬁcally, if it
could be established that the abnormal regurgitant
ﬂow was the initiating event leading to the patient’s
clinical presentation, then the pathogenesis of the MR
could be considered to be valvular, rather than ven-
tricular. Conversely, if an injury to the LV leading to
marked chamber enlargement preceded the onset of
MR, then the regurgitant lesion might not be consid-
ered to be an important determinant of the patient’s
clinical course. Based on such a framework, in a pa-
tient with an acute papillary muscle rupture, the MR
would be regarded as the primary driving mechanism,
even though the disease process did not affect the
valve leaﬂets or chorda tendinae.
However, as in the case of a conceptual framework
based on anatomy, a classiﬁcation that is based on the
sequence of events over time has important de-
ﬁciencies. Many patients present to the clinician for
the ﬁrst time with both signiﬁcant MR together with
meaningful LV dysfunction, and it may be extremely
difﬁcult to accurately ascertain the sequence of
events. More importantly, it is highly plausible that
an LV disorder that causes cardiac dilatation might
secondarily but disproportionately injure the muscle
that supports normal mitral valve coaptation. In such
patients, hemodynamically important degrees of MR
could emerge after the onset of ventricular injury and
early remodeling, but before the development of the
marked ventricular enlargement that (in and of itself)would be sufﬁcient to impair coaptation of the mitral
valve leaﬂets.
CHALLENGES IN QUANTIFYING THE SEVERITY OF
MR. Regardless of whether the regurgitant lesion is
characterized in terms of anatomy or time, it is
important to quantify the volume of mitral regur-
gitant ﬂow. Minor degrees of MR do not require
treatment, whereas severe MR can seriously
compromise stroke volume, which may be particu-
larly deleterious if systolic function is already
impaired. Consensus documents deﬁning severe MR
have consistently used a regurgitant fraction of at
least 50%, that is, one-half of the total stroke volume
is directed backwards into the left atrium instead of
forwards into the aorta (15,16). Given this threshold,
we should ask: what measurements performed during
2-dimensional Doppler echocardiography identify
patients with a regurgitant fraction of at least 50%?
A popular approach to the quantiﬁcation of MR by
Doppler echocardiography is the calculation of the
EROA, most commonly by the proximal isovelocity
surface area (PISA) method (15). Guidance from the
American Society of Echocardiography (16) suggested
that a regurgitant fraction of least 50% generally
corresponded to EROA of 0.4 cm2. However, the
calculation of EROA is fraught with difﬁculties. The
PISA method assumes a round ofﬁce through a ﬂat
surface; however, this assumption is often violated in
patients who have functional MR because the geom-
etry of the regurgitant oriﬁce is often crescent-
shaped; the jets may be eccentric; the proximal
convergence zone is often asymmetric; and regur-
gitant ﬂow changes during systole, typically
following a biphasic pattern (9). Furthermore, the
EROA often cannot be calculated when the MR is
mild; the EROA by 2-dimensional echocardiography
may differ from that calculated by 3-dimensional
methods; and meaningful changes in the calculation
of EROA can be produced by tiny differences in an
observer’s measurement of the PISA radius (9,17,18).
Accordingly, there can be substantial interobserver
disagreement in the quantitative assessment of the
severity of MR, even when the estimation of EROA by
PISA is performed by experts (19).
In part motivated by these uncertainties, guideline
documents in 2012 to 2014 proposed that the identi-
ﬁcation of patients with severe MR might best be
carried out not by precise quantiﬁcation of the visu-
alized regurgitant jet on imaging, but by character-
ization of the presumed inﬂuence of the lesion on the
prognosis of afﬂicted patients (20,21). If a patient with
meaningful degrees of MR had a poor prognosis,
FIGURE 1 Relation of EROA and Regurgitant Volume to LVEDV
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Inﬂuence of LV end-diastolic volume (LVEDV) on the effective regurgitant oriﬁce area
(EROA) (top) and the regurgitant volume (bottom) in patients with a regurgitant fraction
of 50% (i.e., the threshold for severe mitral regurgitation). Relationships are depicted
based on the Gorlin hydraulic oriﬁce equation. (Top) Relationship between EROA and
LVEDV assuming LVEF 30% and severe MR with regurgitant fraction (RF) of 50%. Note
that EROA is inﬂuenced by the square root of the mean systolic pressure gradient be-
tween the LV and LA and the systolic ejection period (assumed to be 300 ms). Three
different lines are shown for patients in 3 different states of heart failure: (pink) a
patient with LV peak systolic pressure 160 mm Hg, LA pressure 16 mm Hg, and peak MR
velocity 6 m/s; (green) a patient with LV peak systolic pressure 120 mm Hg, LA pressure
20 mm Hg, and peak MR velocity (vel) 5 m/s; and (blue) a patient with LV peak systolic
pressure 90 mm Hg, LA pressure 26 mm Hg, and peak MR velocity 4 m/s. To be most
useful, these lines should be depicted in a 3-dimensional space. Nonetheless, the EROA
reaches 0.4 cm2 only at very large LV volumes (>350 ml for blue, 275 ml for green, and
250 ml for pink). Additionally, the EROA is dependent on the pressure gradient between
the LV and LA at a given regurgitant fraction. In a typical patient with heart failure
(depicted by the green line) with an LVEDV 220 to 250 ml, a regurgitant fraction of
50% corresponds to an EROA of 0.30 to 0.35 cm2. (Bottom) Unlike the EROA, the
regurgitant volume is not dependent on pressure gradient, but it is dependent on LVEF.
Note that regurgitant volume never exceeds 60 ml when the LVEF is 20% to 30%, and
exceeds 60 ml in patients with a LVEF of 40% only when the LV is very dilated (i.e.,
LVEDV >300 ml). When the LVEDV is normal, the regurgitant volume can be below 30
ml even when regurgitant fraction is 50%. When the LVEDV is 220 to 250 ml, severe
MR (deﬁned by a regurgitant fraction of 50%) corresponds to a regurgitant volume of
45 ml when the LVEF is 40%, 35 ml when the LVEF is 30%, and <25 ml when the LVEF
is 20%.
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4it was tempting to assume that the regurgitant lesion
must be hemodynamically important, even if the
calculated EROA suggested only mild-to-moderate
MR. As a result, when studies suggested that pa-
tients with an EROA ranging from 0.2 to 0.4 cm2 had
similarly unfavorable clinical outcomes during
follow-up (22–24), the guidelines issued in Europe in
2012 (20) and in the United States in 2014 (21) both
reduced the threshold for the identiﬁcation of severe
functional MR from its earlier value of EROA of 0.4
cm2 down to a new cutoff value of 0.2 cm2. This new
relaxed threshold was used to deﬁne the eligibility
criteria for the MITRA-FR randomized controlled trial
of transcatheter mitral valve repair (12).
However, any isolated interpretation of the calcu-
lated estimate of EROA in an individual patient—
whether it is based on echocardiography or its pre-
sumed association with clinical outcomes—suffers
from the same deﬁciency: both approaches over-
emphasize the assessment or importance of events
taking place at the level of the mitral valve, and they
ignore the critical contribution of LV volume, pres-
sure, and function in determining the hemodynamic
severity and long-term prognosis of patients with
functional MR (9,25).
As we have described previously (9), for any given
regurgitant fraction, the EROA is dependent on both
the left ventricular end-diastolic volume (LVEDV) and
the left ventricular ejection fraction (LVEF) (Figure 1).
If we assume an LVEF of 30% and an LVEDV in the
normal range, a regurgitant fraction >50% can be
associated with an EROA as low as 0.2 cm2. However,
most patients with chronic heart failure with an LVEF
of 30% have meaningful degrees of LV dilatation
(e.g., an LVEDV of 200 to 250 ml); in these patients,
an estimated EROA of 0.2 cm2 reﬂects only modest
degrees of MR. In patients with systolic dysfunction
and a typically enlarged LV, the regurgitant fraction
exceeds 50% only when the EROA is at least 0.3 cm2.
Even higher thresholds of EROA are needed to iden-
tify severe degrees of MR if the LVEF is <30% or the
LVEDV is over 300 ml. Furthermore, the relationship
between EROA and LVEDV is inﬂuenced by the mean
systolic pressure gradient between the LV and left
atrium (LA). Patients with chronic heart failure—who
typically have lower systolic blood pressures but
higher LA pressures—require very high thresholds for
the EROA (e.g., 0.4 cm2) to reliably identify patients
whose regurgitant fraction is at least 50%.
The relationships depicted in Figure 1 lead to an
important conclusion: in patients with a depressed
LVEF, meaningful degrees of chamber enlargement,
FIGURE 2 Relationship Between EROA and LVEDV Illustrating Domains That Deﬁne
Disproportionately Severe, Proportionately Severe, and Nonsevere Functional
Mitral Regurgitation
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Delineation of domains to identify patients with: 1) nonsevere MR; 2) severe MR that is
proportional to left ventricular end-diastolic volume (LVEDV); and 3) severe MR that is
disproportionate to LVEDV. The diagram depicts the relation between effective regur-
gitant oriﬁce area (EROA) and LVEDV, assuming an LVEF of 30% with a regurgitant
fraction of 50%, as in Figure 1A. The blue line represents the hypothetical relationship
when the degree of severe MR is proportional to the LVEDV. The gray area approximates
a degree of uncertainty that is determined by the imprecision inherent in the measure-
ment of EROA as well as the hemodynamic state of the patient (see Figure 1). The pink
area in the upper left depicts severe MR that disproportionate to LV dilation. The
green area in the lower right depicts nonsevere MR. The average patient enrolled in the
MITRA-FR and COAPT trials is shown by the pink dots, based on the information made
public to date.
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5and systolic blood pressures <120 mm Hg, values for
EROA of 0.2 cm2 would indicate the absence of he-
modynamically important degrees of MR. An EROA
of #0.2 cm2 is the inevitable consequence of any
degree of impaired leaﬂet coaptation due to LV
enlargement in a nonhypertensive patient who has
chronic heart failure with a reduced LVEF. This de-
gree of MR is unlikely to be clinically relevant, in light
of evidence that transcatheter mitral valve repair of
patients with functional MR has favorable effects on
LV remodeling of a magnitude similar to mitral valve
replacement even when the degree of residual MR is
1þ or 2þ following a successful procedure (26).
Ignoring the contribution of LV size and function
also can profoundly distort the interpretation of any
study that relies on the clinical course of individual
patients to estimate the severity of mitral valve
dysfunction (16). If meaningful degrees of MR are
seen in a patient whose LV has not adversely
remodeled (i.e., he or she has an LVEDV in the normal
range), the clinical course of the disease can be ex-
pected to be primarily determined by the severity of
the valvular disorder. However, if the LVEDV is 200 to
250 ml (as is typical for many patients with chronic
heart failure and reduced LVEF), the prognosis will be
profoundly inﬂuenced by the disease process in
the LV. An EROA of 0.2 cm2 in these individuals—
indicative of nonsevere MR—may well be associated
with a high rate of morbidity and mortality, but the
adverse outcome is not related to the degree of MR.
In patients whose greatly impaired LV function is
the principal cause of an early death, the degree of
MR should not be automatically considered to be
clinically important simply because the prognosis is
poor.
PROPOSAL FOR A NEW CONCEPTUAL FRAMEWORK.
For purposes of clinical decision-making in functional
MR, the critical issue is not to determine whether the
mitral valve is the site of the disease process, whether
the regurgitant lesion came ﬁrst, or whether the MR is
associated with a poor prognosis. Instead, the prin-
cipal reason to fully characterize and quantify the
determinants of functional MR is to determine if an
intervention directed at the mitral valve is capable of
changing the clinical course of the disease. In patients
with functional MR, the leaﬂets do not have a major
anatomic defect, and the regurgitant jet may emerge
late in the clinical course of the disease. However, if
reducing the regurgitant volume with mitral valve
repair or replacement reduces the risk of death and
hospitalization, then (by deﬁnition) the magnitude of
MR must have been clinically important. Conversely,
if an intervention targeted to the mitral valve yieldsno beneﬁt, it is not reasonable to claim that the MR
was clinically signiﬁcant, regardless of its anatomy or
time of onset.
Viewed through this lens, the precise sequence of
events that may have led to the clinical presentation
of the patient becomes irrelevant. If an intervention
directed at the mitral valve changes the natural his-
tory of the disease, then the MR should be considered
a target for therapy, even if it is “secondary” to LV
dysfunction. We propose a novel terminology for
identifying such patients. In our framework, physi-
cians should seek to determine whether the esti-
mated degree of MR is expected or proportionate to
the degree of LV dilatation, or alternatively, whether
the severity of MR is unexpected or disproportionate
to the degree of LV enlargement (Figure 2). Further-
more, it is important to recognize that nonsevere MR
(generally corresponding to an EROA #0.2 cm2) is
routinely seen in patients with chronic heart failure
whose LV end-diastolic volumes exceed 220 ml or
120 ml/m2 (27,28), and such mild degrees of MR in
patients with a dilated LV are not corrected by mitral
valve repair (29), especially when the LV systolic
dimensions are also increased (27,28). Because they
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6failed to recognize the inﬂuence of the LV, the 2012 to
2014 European and U.S. guidelines misclassiﬁed an
EROA of 0.2 cm2 in patients with meaningful LV
dilatation as severe; fortunately, this error has been
corrected in the 2017 update (30).
Figures 1A and 2 normalize the calculated estimate
for EROA for the LVEDV, thus making it possible to
identify if the MR in a patient or in a population is
“proportionate” or “disproportionate” to the degree
of LV dysfunction. Upper and lower bounds need to
be deﬁned empirically, given the imprecision of the
estimation of EROA and the importance of additional
hemodynamic and echocardiographic variables.
Nonetheless, the overarching principles depicted in
the graph are clear. A patient whose MR severity is
consistent with the amount of LV dilatation would
fall close to the line of proportionality, and thus,
might not be expected to improve following in-
terventions that are directed toward the mitral valve.
Conversely, a patient might respond favorably to a
mitral valve reparative procedure if he or she had
a disproportionately large degree of MR when
compared with the degree of LV dilatation. A patient
with an EROA/LVEDV ratio well below the line of
proportionality has nonsevere MR and would not be
expected to beneﬁt from any intervention directed at
the mitral valve. Amazingly, the validity of this pro-
posed framework appears to have been inadvertently
tested in 2 recently completed randomized controlled
trials of mitral valve repair in patients with chronic
heart failure, systolic dysfunction, and functional or
“secondary” MR.
DESIGN AND RESULTS OF THE MITRA-FR
AND COAPT TRIALS
The MITRA-FR (Percutaneous Repair with the Mitra-
Clip Device for Severe Functional/Secondary Mitral
Regurgitation) trial (NCT01920698) (12) randomly
assigned 307 patients with chronic heart failure, a
reduced LVEF, and severe secondary MR to undergo
transcatheter mitral valve repair or to a control group
that did not undergo the procedure. After 12 months,
patients who were assigned to mitral valve repair
were similar to those in the control group with
respect to the risk of death or the risk of hospitaliza-
tion for heart failure. The hazard ratio was 1.11 (95%
conﬁdence interval [CI]: 0.69 to 1.77) for all-cause
mortality and 1.13 (95% CI: 0.81 to 1.56) for hospital-
ization for heart failure. Although the patients who
underwent mitral valve repair experienced a short-
term reduction in the degree of regurgitant ﬂow, the
use of the device did not reduce LV volumes after
1 year.The COAPT (Cardiovascular Outcomes Assessment
of the MitraClip Percutaneous Therapy for Heart
Failure Patients with Functional Mitral Regurgitation)
trial (NCT01626079) (13) randomly assigned 614 pa-
tients with chronic heart failure, a reduced LVEF, and
severe secondary MR to undergo transcatheter mitral
valve repair or to a control group that did not undergo
the procedure. After 2 years, patients who were
assigned to mitral valve repair had a lower risk of
death from any cause and a lower risk of hospitali-
zation for heart failure. The hazard ratio for all-cause
mortality at 2 years was 0.62 (95% CI: 0.46 to 0.82;
p < 0.001). The hazard ratio for the annualized rate of
all hospitalizations for heart failure at 2 years was
0.53 (95% CI: 0.40 to 0.70; p < 0.001). In contrast with
the ﬁndings of the MITRA-FR trial, mitral valve repair
led to a signiﬁcant reduction in LV volumes after 1
year of follow-up.
How can these apparently discordant results be
explained? Prior to randomization, medical therapy
was supposed to be titrated to maximally tolerated
doses in the COAPT trial, but such a requirement
was not part of the design of the MITRA-FR study.
However, neither trial has reported precisely what
medical treatments were used and what doses of
speciﬁc drugs were achieved. Both trials reported a
high prevalence of use of classes of drugs that are
known to prolong life, but the use of neprilysin in-
hibitors in both trials was low. Although it is possible
that patients in the MITRA-FR trial received less
aggressive medical therapy, we currently have little
data to support such a conclusion. Even if it were
true, the authors of the COAPT trial have not
explained why a difference in background drug
treatment would explain the discordant results across
the 2 studies. Interestingly, in the COAPT trial—even
though medical therapy was supposed to have been
maximized prior to randomization—drug treatments
were intensiﬁed to a greater degree in the device than
in the control arms during the follow-up period. This
degree of intensiﬁcation may have been related to the
fact that blood pressure increases in many patients
who undergo transcatheter mitral valve repair (30),
thus potentially allowing for further up-titration of
medical therapy. Changes in medical therapy during
follow-up in the MITRA-FR trial are yet to be
reported.
It might be tempting to propose that regional dif-
ferences in medical practice might have contributed
to the different results of the 2 trials. The MITRA-FR
trial was carried out principally by investigators in
France, whereas the COAPT trial was executed pri-
marily in the United States and Canada. Were the
North American investigators more experienced and
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7more likely to have implanted a successful device?
There is no reason to support such speculation. The 2
trials used precisely the same device to reduce MR
severity, and the proportion of patients with residual
3þ or 4þ mitral regurgitation immediately following
completion of the procedure was <10% in both
studies (12,13).
The MITRA-FR and COAPT trials were developed
by distinct groups of investigators, and not unex-
pectedly, the primary endpoints of the 2 trials were
somewhat different, and the studies used slightly
different statistical approaches to their analysis of
events. The COAPT trial was larger and longer in
duration than the MITRA-FR trial, and thus, it
recorded more major adverse cardiovascular events.
However, the strikingly different ﬁndings across the 2
trials cannot be explained by differences in trial
design, length of follow-up, or statistical power.
RECONCILING THE FINDINGS OF THE
MITRA-FR AND COAPT TRIALS
Intriguingly, an examination of the baseline charac-
teristics of the patients participating in the 2 trials
indicates that the studies enrolled 2 distinctly
different groups. The MITRA-FR investigators
enrolled patients who had striking LV dilatation but
relatively modest degrees of MR. Prior to randomi-
zation, the mean LVEDV was 252 ml and the mean
EROA was 31 mm2. As can be seen in Figure 2, these
features are consistent with a degree of MR that is
severe, but proportional to the degree of LV dilata-
tion. In contrast, the COAPT investigators primarily
enrolled patients in whom the degree of MR was
disproportionately great compared with the degree of
LV chamber enlargement. Prior to randomization, the
mean LVEDV was 192 ml and the mean EROA was
41 mm2. Therefore, when the patients enrolled in
the COAPT trial are compared with those in the
MITRA-FR trial, the EROA was approximately 30%
higher but their LV volumes were approximately
30% smaller. When these features are displayed
in Figure 2, it is evident that—in contrast with
the patients in the MITRA-FR trial—the patients in
the COAPT study had disproportionate degrees of MR.
Differences in the entry criteria for the two trials
likely explain why the studies enrolled distinctively
different groups of patients. The deﬁnition of severe
MR in the MITRA-FR trial was based on the 2012
deﬁnition speciﬁed in the European guidelines (20);
52% of the patients had an EROA <0.3 cm2, and only
16% had a EROA $0.4 cm2. Furthermore, patients
with marked LV dilatation were not excluded: 70%
of the patients had a LV end-diastolic dimension>65 mm. In contrast, in the COAPT trial, only 14%
of the patients had an EROA <0.3 cm2, but 41%
had an EROA $0.4 cm2. In addition, the COAPT trial
did not allow participation of patients with striking
degrees of LV enlargement; that is, those with an
end-systolic dimension >70 mm were not eligible for
randomization.
Interestingly, the requirement in the COAPT trial
that patients receive maximally tolerated medical
therapy may also have promoted the inclusion of
patients who had disproportionate MR into the study.
Effective drug and device treatments for heart failure
can have profoundly favorable effects on cardiac
remodeling and LV geometry, and thus, these should
be expected to reduce the magnitude of MR that is
related to LV dilatation (3–5). Therefore, it is possible
that patients whose MR was proportionate to their LV
volumes may have responded so favorably to medical
therapy (with respect to the magnitude of regurgitant
ﬂow) that they were no longer eligible for participa-
tion in the COAPT trial. In contrast, patients with
disproportionate MR might not be expected to have
their regurgitation be adequately ameliorated by in-
terventions that reduce LV volumes, and thus, these
patients may have been preferentially enrolled in
COAPT.
In contrast, most of the participants in the MITRA-
FR trial appeared to have proportionate MR (Figure 2),
that is, their regurgitant ﬂow was related more to LV
dilatation than to a reparable defect in mitral valve
coaptation. If the LV is markedly dilated at the time of
the procedure and remains so during long-term
follow-up (as was the case in the MITRA-FR trial), it
may be difﬁcult to achieve and maintain coaptation of
the valve leaﬂets by the use of mechanical clips.
Therefore, it seems likely that the marked LV
enlargement of the participants—rather than the
expertise of the operators—explains the lower rates of
procedural success during long-term follow-up. In the
COAPT trial, the proportion of patients with 3þ or 4þ
MR was 5% immediately following the procedure, and
remained unchanged at 5% after 1 year. In contrast, in
the MITRA-FR trial, the proportion of patients with
3þ or 4þ MR was 9% after device placement and
increased to 17% after 1 year.
Importantly, the results of the 2 trials demonstrate
that it is not possible to distinguish patients who have
proportionate or disproportionate MR by examining
their overall rates for death and hospitalization for
heart failure. The annualized rates for these 2 major
adverse clinical outcomes were similar in the
medically-treated groups in the MITRA-FR and
COAPT trials. However, the rate of these events may
have been primarily related to LV dysfunction in the
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COAPT trial. Interestingly, in another randomized
trial of patients with moderate-to-severe MR, trans-
catheter mitral valve repair did not reduce MR as
effectively as mitral valve surgery. Yet, the percuta-
neous procedure yielded the most favorable
comparative results in patients who had functional
MR that was associated with modest impairment of
LV function (10,31).
IMPLICATIONS FOR CARDIAC IMAGING
The concepts depicted in Figure 2 represent true (not
measured) values for EROA, LVEDV, and LVEF. Two-
dimensional echocardiography is the most widely
used imaging technique to measure these parameters
in clinical practice and in most clinical trials. How-
ever, EROA may be systematically overestimated by
PISA because it typically only measures the largest
value in systole and assumes a constant value
throughout systole (16). Furthermore, 2-dimensional
echocardiography is prone to underestimating LV
volumes due to foreshortening as well as due to fail-
ure to align the imaging plane to the center of the LV
cavity and to identify the endocardial borders in all
segments. The use of an ultrasound contrast agent
can improve accuracy of LV volumes (32), and 3-
dimensional echocardiography is currently recom-
mended for LV volume measurement when image
quality is good enough to allow visualization of
endocardial borders (33). Cine magnetic resonance
imaging provides the most accurate and reproducible
measurements of LV volumes and LVEF, which can
also be assessed by current multidetector computed
tomography with single beat acquisition. Generally,
MR is quantiﬁed by magnetic resonance imaging by
comparing LV total stroke volume to forward stroke
volume to obtain regurgitant volume and fraction
(16,33). Both cine magnetic resonance imaging and
computed tomography have been shown to be
capable of measuring the anatomic EROA directly
(34). Clearly, further studies are needed to determine
the best methodology for distinguishing patients with
disproportionate from those with proportionate sec-
ondary MR and to deﬁne optimal thresholds for
measured, as opposed to theoretical, values for these
parameters.
CONCLUSIONS
If we accept the results of both the MITRA-FR and
COAPT trials at face value, then the totality of avail-
able evidence suggests that patients with chronic
heart failure respond favorably to transcathetermitral valve repair if they exhibit degrees of MR that
are disproportionately greater than might be ex-
pected from the degree of LV chamber enlargement.
The COAPT trial focused primarily on patients with
“disproportionate” MR, and such patients beneﬁtted
from mitral valve repair. In contrast, the MITRA-FR
trial focused primarily on patients with “proportion-
ate” MR (which was related to LV enlargement and
remodeling), and these patients did not beneﬁt from
transcatheter mitral valve repair. We should not
conclude that the 2 trials enrolled similar types of
patients simply because they both focused on in-
dividuals with “severe” functional MR who had
comparable annualized rates of morbidity and
mortality.
Further analyses of the 2 trials are well-positioned
to conﬁrm or refute our proposed framework. We
expect that—when the patient-level data from the 2
trials are combined—those with disproportionate MR
will be shown to beneﬁt from transcatheter mitral
valve repair, regardless of whether an individual
participated in the COAPT trial or in the MITRA-FR
study. We also anticipate that the pretreatment LV
volume will be shown to inﬂuence the procedural
success rates (as deﬁned by absence of MR), particu-
larly in the long-term, thus explaining the higher 1-
year rates of meaningful post-procedural MR in
MITRA-FR than in COAPT. We hypothesize that the
ratio of EROA to LV end-diastolic volume is likely to
be useful in individual clinical decision-making, that
is, patients with proportionate MR might be highly
likely to respond to the optimization of medical
therapy, whereas those with disproportionate MR
would be most likely to beneﬁt from additional
transcatheter repair (35). We look forward to having
these hypotheses tested in future analyses. Until
then, our proposed framework is consistent with our
current understanding of the pathophysiology of MR
and is fully concordant with the reported ﬁndings of
the 2 randomized controlled trials of transcatheter
mitral valve repair.
Our proposed framework should not be confused
with the term “mixed primary and secondary” MR.
The designation of a “mixed” lesion was developed to
recognize the existence of more than 1 causal mech-
anism of MR, but without the ability to provide
guidance with respect to the preferred options for
treatment. In contrast, our proposal to assess the
degree of proportionality or disproportionality in
the evaluation of severe MR is intended to deﬁne
distinct groups within the conventional category of
“secondary” or “functional” MR to provide speciﬁc
recommendations for clinical decision-making. Our
framework makes no assumptions about causation.
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9If our proposed framework is conﬁrmed, it is
conceivable that the term “secondary” to characterize
MR due to LV dysfunction may have outlived its use-
fulness. All MR is secondary to an abnormality of 1 or
more components of the mitral apparatus, including
the LV. “Functional” MR has also been used to
describe MR secondary to LV disease, but the term
does not clarify which patients beneﬁt from the
mechanical correction of MR or might be better
managed with drug or device treatments. Both the
degree and the determinants of “secondary” MR are
highly dynamic (Figures 1 and 2), and current treat-
ments for heart failure modulate these dynamic con-
ditions. In distinguishing valvular from ventricularcontributions to MR, the critical question is not
whether a lesion is “primary” or “secondary,” but
whether the magnitude of MR can be explained by the
degree of LV dilatation. In patients with severe MR
and impaired systolic function, the terms “propor-
tionate” and “disproportionate” help identify which
patients beneﬁt from medical treatments that target
the LV or from transcatheter interventions that target
the mitral valve.
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